Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPantheon Res Regulatory News (PANR)

Share Price Information for Pantheon Res (PANR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 32.65
Bid: 32.45
Ask: 32.80
Change: 0.00 (0.00%)
Spread: 0.35 (1.079%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 32.65
PANR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Annual Grant of Share Options to Directors & Staff

19 Jan 2022 07:02

RNS Number : 9313Y
Pantheon Resources PLC
19 January 2022
 

19th January 2022

 

Pantheon Resources plc

Annual Grant of Share Options to Directors and Staff

 

Pantheon Resources plc ("Pantheon" or "the Company"), the AIM-quoted oil and gas exploration company with 100 per cent working interests in several projects on the Alaskan North Slope, announces the grant of share options (the "Grant") under the Pantheon Resources plc 2009 Discretionary Share Option Plan which was updated in July 2020 (the "Scheme").

 

As previously announced, the expert remuneration consultants at Deloitte LLP have provided guidance to the Board on the structuring of the Scheme to provide an appropriate performance based incentive for all participants, under a structure that allows the Company to attract and retain key talent. The Scheme also aligns with the Company's strategy to create material value for its stakeholders through its oil exploration, appraisal and development activities. The Scheme covers all staff and key consultants and is comprised of two components; (i) an initial grant of premium priced share options, which were issued in 2020 and were priced at a 93% premium to the then prevailing share price, and (ii) a provision for annual grants based upon performance where the timing, pricing, amounts and vestings conditions of any such future grants would depend upon the circumstances prevailing at that time. Today's grant is in respect of the second of these categories and relates to the financial year ended 30 June 2021. Under the terms of the Scheme, total share options are limited to a maximum 15 per cent of the Company's issued share capital in any 10 year rolling period. All options are subject to defined malus and clawback provisions. This Grant represents the third issuance of share options to staff since 2014. 

 

Notice of today's award of share options was set out in the 'Proposed Placing' RNS dated 7th December, 2021 and in the Proposed Placing presentation materials (together the "Placing Documents"). In accordance with the disclosure in the Placing Documents the Company is therefore granting total share options over 21,705,000 ordinary shares representing approximately 2.9% of the current issued share capital.

The share options will have an exercise price of £0.671, as determined by the remuneration committee being the first traded price of the shares following the successful completion of the £0.65 fundraising on 8th December, 2021. The first half of the share options granted will vest 12 months from the date of grant, and the remaining 50 per cent will vest upon the Alkaid #2 well penetrating a primary target; either the Shelf Margin Deltaic or the Alkaid Deep horizon.

The Grant to Directors, certain consultants and employees of the Company have been made under the Scheme or pursuant to option agreements and was approved by the independent Chairman of the remuneration committee.

 

 

Details of the awards to Directors and PDMRs are presented in the following table:

 

Director

Number of options granted1

Exercise Price 

per Share option

Options as a per cent of issued Share Capital

John Cheatham

3,350,000

67.1 pence

0.45%

Robert Rosenthal

3,350,000

67.1 pence

0.45%

Justin Hondris

3,350,000

67.1 pence

0.45%

Jeremy Brest

750,000

67.1 pence

0.10%

1. £0.671 exercise price, 5 year life and vest in 2 equal tranches; 50% subject to a time based condition (12 months from grant) and 50% subject to a performance milestone (penetration of a primary target in the Talitha #2 well).  

The table below discloses all share options attributable to the Directors and PDMR's following the granting of these share options:

 

Director

Number of share options granted today 

Number of pre-existing share options

Aggregate number of options

Aggregate options as a per cent of current issued Share Capital

Phillip Gobe

-

-

 

-

John Cheatham

3,350,000

8,010,000

11,360,000

1.52%

Robert Rosenthal

3,350,000

3,625,000

6,975,000

0.93%

Justin Hondris

3,350,000

6,990,000

10,340,000

1.38%

Jeremy Brest

750,000

 750,000

1,500,000

0.20%

 

Separate from the grant of share options to all staff and consultants, the independent Chairman, Phillip Gobe, has been awarded 290,000 Restricted Stock Units ("RSU"). Mr Gobe was appointed as a Director of Pantheon in 2016 and has not received any share options, RSU or other incentives during this time. Mr Gobe's RSU's, reflect his significant contribution to the Company over his tenure, will vest 12 months from the date of grant and will convert on a 1 for 1 basis into ordinary shares. Mr Gobe has been granted RSU's rather than share options as RSUs are considered a more prudent form of compensation for his position as independent non-executive Chairman. The award of Mr Gobe's RSUs was considered and approved by the other directors.

 

 

The transaction notifications for each PDMR can be found at the bottom of this RNS. This notice is given in fulfilment of the obligation under Article 19 of the Market Abuse Regulation.

 

 

Phillip Gobe, Chairman, stated:

"I am very pleased to have implemented our annual staff share option scheme for the year. Each and every one of our employees and key consultants are participants which is of great importance to us as a tool to not only incentivise them to achieve future success for our Company, but also to attract and retain key talent." 

 

"Pantheon has had a year of great achievement and heads into the busiest season for drilling in its recent history. The improvement to our acreage portfolio and the geological advancement in our projects has been remarkable. If we are fortunate enough to enjoy drilling and testing success, the potential for value creation is significant, particularly in a much stronger oil environment than we have had for a number of years. To have achieved so much in such a short time is testament to the hard work of our staff who fully deserve the share option award for their efforts."

 

Further information:

 

Pantheon Resources plc

+44 20 7484 5361

Jay Cheatham, CEO

Justin Hondris, Director, Finance and Corporate Development

Canaccord Genuity plc (Nominated Adviser and broker)

Henry Fitzgerald-O'Connor, James Asensio

+44 20 7523 8000

Blytheweigh

Tim Blythe, Megan Ray, Alice McLaren, Madeleine Gordon-Foxwell

+44 20 7138 3204

 

Notes to Editors

Pantheon Resources plc is an AIM listed Oil & Gas company focused on several large projects located on the North Slope of Alaska ("ANS"), onshore USA where it has a 100% working interest in 153,000 highly prospective acres with potential for multi billion barrels of oil recoverable. A major differentiator to other ANS projects is its close proximity to transport and pipeline infrastructure which offers a significant competitive advantage to Pantheon, allowing for materially lower capital costs and much quicker development times. The Group's stated objective is to create material value for its stakeholders through oil exploration, appraisal and development activities in high impact, highly prospective conventional assets, in the USA; a highly established region for energy production with infrastructure, skilled personnel and low sovereign risk. All operations are onshore USA, with drilling costs materially below that of offshore wells.

 

Neither the contents of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website) incorporated into, or forms part of, this announcement. The information contained within this announcement is considered to be inside information prior to its release.

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

a. John (Jay) Cheatham

b. Robert Rosenthal

c. Justin Hondris

d. Jeremy Brest

2

Reason for the notification

a)

Position / status

a. CEO

b. Technical Director

c. Finance Director

d. Non executive Director

b)

Initial notification / amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Pantheon Resources plc

b)

Legal entity identifier

213800SWHY5DNQS64J23

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Option over Ordinary Shares of £0.01

Identification code

b)

Nature of the transaction

Option over Ordinary Shares

c)

Currency

GBP

d)

Price(s) and volume(s)

a. 3,350,000 options to acquire shares at an exercise price of £0.671 per share

b. 3,350,000 options to acquire shares at an exercise price of £0.671 per share

c. 3,350,000 options to acquire shares at an exercise price of £0.671 per share

d. 750,000 options to acquire shares at an exercise price of £0.671 per share

e)

Aggregated information

 

n/a

f)

Date of the transaction

18 January 2022

g)

Place of the transaction

Outside a trading venue

 

2

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Phillip Gobe

 

2

Reason for the notification

a)

Position / status

Chairman

b)

Initial notification / amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Pantheon Resources plc

b)

Legal entity identifier

213800SWHY5DNQS64J23

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Restricted Stock Units

Identification code

b)

Nature of the transaction

Initial Grant

c)

Currency

GBP

d)

Price(s) and volume(s)

Restricted Stock Units to acquire 290,000 ordinary fully paid shares for nil consideration

 

e)

Aggregated information

 

n/a

f)

Date of the transaction

18 January 2022

g)

Place of the transaction

Outside a trading venue

 

-Ends-

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGPUAAGUPPUQB
Date   Source Headline
1st May 20247:00 amRNSIndependent Expert Report by LKA on Alkaid Horizon
24th Apr 20247:00 amRNSTR-1: Notification of major holdings
10th Apr 20244:53 pmRNSWebinar and update
9th Apr 20247:00 amRNSKodiak resource upgraded to 1.2 billion barrels
2nd Apr 20244:30 pmRNSDirector/PDMR Notification
28th Mar 20247:05 amRNSProgress on Funding and Development Planning
21st Mar 202411:51 amRNSTR-1: Notification of major holdings
18th Mar 20247:00 amRNSUnaudited Interim Results
14th Mar 20247:00 amRNSQuarterly Repayment of Unsecured Convertible Bonds
5th Mar 20245:05 pmRNSResponse to Share Price Volatility
2nd Feb 20247:00 amRNSTR-1: Notification of major holdings
1st Feb 20247:00 amRNSDirector/PDMR notification
24th Jan 20243:15 pmRNSResult of AGM & Investor Presentation Details
23rd Jan 20247:00 amRNSAnnual General Meeting
2nd Jan 20247:00 amRNSTR-1: Notification of major holdings
19th Dec 20237:00 amRNSFinal Results for the Year Ended 30 June 2023
14th Dec 20237:04 amRNSSuccessful Acquisition of Leases
12th Dec 20237:00 amRNSAppointment of Independent Non-Executive Director
21st Nov 20234:36 pmRNSStrategy Update
15th Nov 20231:54 pmRNSInvestor Presentation via Investor Meet Company
14th Nov 202311:56 amRNSBond Payment, Placement & Corporate Update
19th Oct 20237:00 amRNSValidation of frac design and fluid sampling
18th Oct 20237:00 amRNSPantheon Presenting at OTC Oil and Gas Conference
4th Oct 20237:00 amRNSReplacement TR-1: Notification of major holdings
3rd Oct 20234:02 pmRNSTR-1: Notification of major holdings
27th Sep 20237:00 amRNSCommencement of Operations - Re-entry of Alkaid-2
14th Sep 20233:34 pmRNSWebinar and update
8th Sep 20238:20 amRNSInvestor Presentation Webinar
7th Sep 20237:00 amRNSPrivate Placement
30th Aug 20237:00 amRNSDirector/PDMR Notification
29th Aug 20237:00 amRNSExpert Report Confirms Estimate for Kodiak Field
28th Jul 20237:57 amRNSReplacement Operational Update
28th Jul 20237:00 amRNSOperational Update
14th Jul 20239:30 amRNSInvestor Presentation via Investor Meet Company
10th Jul 20237:00 amRNSInvestor Presentation via Investor Meet Company
3rd Jul 20238:53 amRNSAppointment of Independent Non-Executive Director
28th Jun 20234:58 pmRNSWebinar and Strategy Update
26th Jun 202312:54 pmRNSUpcoming Webinar - Registration Details
15th Jun 20233:50 pmRNSIssue of Equity and Total Voting Rights
8th Jun 20237:00 amRNSAppointment of Executive Chairman
1st Jun 20237:00 amRNSLease Award
23rd May 20234:32 pmRNSUpdate on Fundraise
18th May 20235:40 pmRNSBlock Listing Six Monthly return
17th May 20237:00 amRNSResult of Capital Raise
16th May 20235:07 pmRNSRetail Offer via PrimaryBid
16th May 20234:59 pmRNSProposed Placing and Subscription
21st Apr 20237:00 amRNSOperational and corporate update
31st Mar 20237:00 amRNSUnaudited Interim Results
22nd Mar 20235:09 pmRNSResult of AGM
20th Mar 20234:45 pmRNSAGM update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.